PFG
MDGL icon

PAX Financial Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

PAX Financial Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,296
Closed -$530K – 231
2023
Q2 		$530K Buy
2,296
+341
+17% +$92.4K 0.12% 154
2023
Q1 		$474K Buy
+1,955
New +$533K 0.11% 155

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PAX Financial Group's MDGL Position: Q3 2023 in Review

PAX Financial Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 2,296 shares — an estimated $530K sold.

PAX Financial Group first reported a position in MDGL in Q1 2023 and held it in 2 quarters. The position peaked at $530K in Q2 2023. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • PAX Financial Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • PAX Financial Group sold 2,296 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $530K.
  • PAX Financial Group first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • PAX Financial Group's Madrigal Pharmaceuticals position peaked at $530K in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on PAX Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.